DNA甲基化谱分析在脑膜瘤当代管理中的作用
本文综述DNA甲基化谱分析在脑膜瘤分类与预后预测中的作用。基于无监督方法构建的生物学分类系统优于WHO分级预测预后,甲基化液体活检亦展现潜力。作者倡导广泛采用这些方法以推动个体化诊疗和临床试验设计。
要点
- DNA甲基化分类系统对脑膜瘤预后的预测能力优于WHO分级。
- 基于甲基化的液体活检在脑膜瘤中展现应用潜力。
- 作者倡导广泛采用甲基化谱分析以推动个体化诊疗和临床试验设计。
核心结论
- DNA甲基化谱分析在脑膜瘤中具有革命性意义,需要广泛采用这些方法以实现个体化诊疗并为临床试验设计提供依据。
研究设计与样本
- 本文为综述,回顾了脑膜瘤中基于DNA甲基化的分类与预后预测工具,包括生物学分类器、预后预测模型和液体活检模型。
主要发现
- DNA甲基化已成功用于脑膜瘤的生物学分类和预后判断。
- 多个研究组提出的新型分子分类系统彼此特征相似,在预测预后和解释亚组特异性生物学过程方面优于WHO分级。
- 近期研究提示基于甲基化的液体活检在脑膜瘤中具有应用潜力,是值得进一步探索的方向。
临床怎么用
- 作者倡导广泛采用DNA甲基化谱分析方法,以推动脑膜瘤的个体化诊疗和临床试验设计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The last decade has seen major international research efforts focus on better understanding disease heterogeneity in meningioma. Multiple molecular platforms have generated significant biological and clinical utility, and there is a need to translate these findings into routine clinical practice. Here we review the role of DNA methylation profiling in meningioma and advocate for its widespread adoption. METHODS: We review modern DNA methylation-based classification and outcome prediction tools in meningioma. Biological classifiers, which were constructed agnostic to outcome using unsupervised approaches, outcome predictors, and liquid biopsy models are discussed in detail. RESULTS: DNA methylation has been used for biological classification and outcome in meningioma with considerable success. Several groups have proposed novel molecular classification systems which share similar features with one another and outperform WHO grade in their ability to predict outcome and explain subgroup-specific biological processes. In addition, recent studies have suggested a role for methylation-based liquid-biopsy in meningioma, which represents an exciting avenue for further exploration. CONCLUSIONS: DNA methylation profiling has been revolutionary in meningioma. There is a need for widespread adoption of these approaches to personalize care and inform clinical trial design.
引用
- Landry AP, Yefet LS, Wang JZ, et al. Methylation profiling in the contemporary management of meningioma. J Neurooncol. 2024. PMID: 39306649. doi:10.1007/s11060-024-04825-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。